IP Library › Granted Patent US 8,455,627
Granted Patent B2
US 8,455,627 · App. 12/877,003 · Granted Jun 4, 2013

Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa

Inventors: Claudia Linhard (Schwetzingen, DE); Stefan Knackmuss (Plankstadt, DE); Melvyn Little (St. Peter-Ording, DE); Karlheinz Peter (Hawthorn East, AU); Peter Roettgen (Ladenburg, DE); Meike Schwarz (Rastatt, DE)
Assignee: Affimed Therapeutics, AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,455,627
App. No.
12/877,003
Granted
Jun 4, 2013
Kind
B2
Abstract

The present invention is directed to an antibody or derivative thereof of human origin for inhibiting platelet aggregation, characterized in that it is effective by substantially exclusive binding to the activated state of platelet integrin receptor GPIIb/IIIa.

Claims (7)

1. An antibody of human origin, wherein said antibody inhibits platelet aggregation and has a greater binding affinity to the activated state of platelet integrin receptor GPIIb/IIIa than to the inactive conformation of the platelet integrin receptor GPIIb/IIIa, wherein the antibody is a single chain antibody or Fab fragment, and wherein the antibody comprises heavy chain variable and light chain variable domains, wherein said antibody comprises

(i) a heavy chain variable domain comprising CDR1 and CDR2 of the heavy chain variable domain encoded by nucleic acids comprising nucleotides 9 to 399 of SEQ ID NO:3 and CDR3 having the sequence as set forth in SEQ ID NO:163 and a light chain variable domain comprising CDR1 and CDR2 of the light chain variable domain encoded by nucleic acids comprising nucleotides 432 to 810 of SEQ ID NO:3 and CDR3 having the sequence as set forth in SEQ ID NO:170 or SEQ ID NO:171; or

(ii) a light chain variable domain encoded by nucleic acids comprising nucleotides 432 to 810 of SEQ ID NO:3, wherein the CDR3 encoded by SEQ ID NO:3 is replaced by a CDR3 having the sequence as set forth in SEQ ID NO:170 or SEQ ID NO:171; or

(iii) a heavy chain variable domain encoded by nucleic acids comprising nucleotides 9 to 399 of SEQ ID NO:3, wherein the CDR3 encoded by SEQ ID NO:3 is replaced by a CDR3 having the sequence as set forth in SEQ ID NO:163.

2. The antibody according to claim 1 , wherein the heavy chain variable domain comprises the sequence as set forth in SEQ ID NO:172.

3. The antibody according to claim 1 , wherein the light chain variable domain comprises the sequences as set forth in SEQ ID NO:173.

4. The antibody according to claim 1 , wherein the variable domains of the heavy and light chains are of a single chain antibody or a Fab fragment.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2011
From: BUETTNER, CLAUDIA; KNACKMUSS, STEFAN; LITTLE, MELVYN; ROETTGEN, PETER
To: AFFIMED THERAPEUTICS, AG
Reel/Frame 026565/0048 →
Priority Claims (1)
EP 01123851 · Oct 5, 2001 · regional
Continuity (2)
Continuation In Part 10491766
Related Publication 20110165175A1 · Jul 7, 2011